Novo Nordisk, Qualcomm, Caterpillar, CSP and Epsilon Energy are included in this Analyst Blog.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
A plan by Hims & Hers Health to sell legal copies of Novo Nordisk weight loss drug Wegovy is drawing pushback from the industry, and bringing new attention to an area of concern for public-health officials. Enormous demand has created shortages of Novo’s Wegovy, as well as a competing weight loss injection from Eli Lilly called Zepbound. Both companies are spending billions of dollars to increase their manufacturing capacity, but the availability of the medicines is limited in the U.S., according to the Food and Drug Administration.